ArticlePloS one2025
Survival benefits of Cytoreductive Nephrectomy in patients with metastatic renal cell carcinoma: evidence from a SEER-based retrospective cohort study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Large sarcomatoid chromophobe renal cell carcinoma with tumor thrombus extending into the inferior vena cava: a case report on the challenges and lessons from a fatal outcome.Annals of translational medicine · 2026Article
- Real-world drivers of treatment choices in synchronous metastatic renal cell carcinoma.BJUI compass · 2026Article
- IFI44 Promotes Clear Cell Renal Cell Carcinoma Progression via PRDX1 and Predicts Poor Prognosis.Research (Washington, D.C.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic renal cell carcinoma (mRCC) is associated with poor prognosis, with a 5-year survival rate of less than 15%. Cytoreductive nephrectomy (CN) has historically played a critical role in mRCC management, potentially enhancing systemic therapy efficacy by reducing tumor burden. However, its relevance in the era of targeted therapies and immune checkpoint inhibitors (ICIs) has been questioned.
objectiveThis study evaluates the survival benefits of CN in mRCC patients using real-world, population-based data from the SEER database.
methodsA retrospective cohort analysis of 6,030 mRCC patients was performed using data from 2010 to 2017. Propensity score matching (PSM) minimized selection bias, yielding 1,350 matched patients. Kaplan-Meier survival curves and multivariate Cox proportional hazards models assessed the impact of CN on overall survival (OS) and RCC-specific survival (CSS), stratified by demographic and clinical characteristics.
resultsCN was associated with a 71% reduction in all-cause mortality (HR = 0.29, 95% CI = 0.25-0.33) and RCC-specific mortality (HR = 0.29, 95% CI = 0.25-0.34). Five-year OS rates were 31.5% in the CN group versus 3.6% in the non-CN group. Survival benefits were consistent across subgroups, including patients with high-grade or advanced-stage tumors, underscoring the role of CN within multimodal treatment strategies.
conclusionCN confers significant survival advantages in mRCC, even in challenging clinical scenarios. These findings reinforce the importance of integrating CN into multimodal therapeutic frameworks, particularly alongside modern systemic therapies. Further prospective studies are warranted to optimize patient selection and treatment sequencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.